ImmediapressPharmascience Inc. contributes to the Montreal Heart Institute’s COLchicine Cardiovascular Outcome Trial (COLCOT), a landmark study to benefit cardiovascular patients and the healthcare system Di Redazione - 16 Novembre 2019 CondividiFacebook Twitter WhatsApp Linkedin Email Print Telegram